[1. A. Walsem, R. Nixon, P. Guyot, A. Karabis and A. R. Moore, Relative benefit-risk comparing diclofe nac to other traditional non-steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors in patients with osteoarthritis or rheumatoid arthritis, Arthritis Res. Ther.19 (2015) 66–72; https://doi.org/10.1186/s13075-015-0554-010.1186/s13075-015-0554-0441179325879879]Search in Google Scholar
[2. A. Pyka, Detection progress of selected drugs in TLC, Biomed. Res. Int.2014 (2014) Article ID 732078 (19 pages); https://doi.org/10.1155/2014/73207810.1155/2014/732078391429624551853]Search in Google Scholar
[3. M. Dołowy and A. Pyka-Pająk, Development of new procedures for the detection and separation of salicylic acid and acetylsalicylic acid using thin-layer chromatography with densitometry, J. Planar Chromatogr. – Modern TLC30 (2017) 363–374; https://doi.org/10.1556/1006.2017.30.5.510.1556/1006.2017.30.5.5]Search in Google Scholar
[4. W. Parys, K. Bober, A. Pyka-Pająk and M. Dołowy, The application of TLC and densitometry for quantitative determination of meloxicam in tablets, Curr. Pharm. Anal.15 (2019) 785–794; https://doi.org/10.2174/157341291566619021215574010.2174/1573412915666190212155740]Search in Google Scholar
[5. M. Starek and J. Krzek, TLC determination of meloxicam in tablets and after acidic and alkaline hydrolysis, Acta Pol. Pharm. Drug Res.69 (2012) 225–235.]Search in Google Scholar
[6. N. Desai and P. Amin, Stability indicating HPTLC determination of meloxicam, Indian J. Pharm. Sci.70 (2008) 644–647; https://doi.org/10.4103/0250-474X.4540610.4103/0250-474X.45406303829221394264]Search in Google Scholar
[7. M. Starek, Separation and determination of four oxicams in pharmaceutical formulations by thin-layer chromatographic-densitometric method, J. Planar Chromatogr. – Modern TLC24 (2011) 367–372; https://doi.org/10.1556/JPC.24.2011.5.110.1556/JPC.24.2011.5.1]Search in Google Scholar
[8. H. Hopkała and A. Pomykalski, TLC analysis of inhibitors of cyclooxygenase and videodensitometric determination of meloxicam and tiaprofenic acid, J. Planar Chromatogr. – Modern TLC16 (2003) 107–111; https://doi.org/10.1556/JPC.16.2003.2.410.1556/JPC.16.2003.2.4]Search in Google Scholar
[9. J. Shaji and D. Varkey, Development of a validated stability-indicating HPTLC method for determination of meloxicam in bulk and pharmaceutical formulations: Pertinence to ICH guidelines, Int. J. Pharm. Pharm. Sci.4 (2012) 160–169.]Search in Google Scholar
[10. B. Mamatha, G. Ushasree and V. U. Maheswara Rao, Analytical techniques for estimation of meloxicam in bulk and pharmaceutical dosage forms: A review, Int. J. Pharm. Res. Anal.5 (2015) 74–77.]Search in Google Scholar
[11. A. Noreen, S. Ahmed, Z. Anwar and I. Ahmad, Analytical techniques for determination of meloxicam in pharmaceutical formulations and biological samples, Baqai J. Health Sci.19 (2016) 59–74.]Search in Google Scholar
[12. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), ICH, Geneva 2005; http://www.ich.org; last access date March 15, 2019.]Search in Google Scholar